

23 December 2024

ImmuPharma PLC
("ImmuPharma" or the "Company")

Change of Auditor

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, announces the appointment of Crowe LLP ("Crowe") as the Company's new auditor, succeeding CLA Evelyn Partners Limited, with immediate effect.

Crowe will conduct the audit of the Company's financial statements for the financial year ending 31 December 2024 and a proposal to reappoint them as auditors of the Company will be subject to the approval of shareholders at the 2025 Annual General Meeting.

For further information please contact:

ImmuPharma PLC (www.immupharma.com)	+44 (0) 207 206 2650
Tim McCarthy, Chief Executive Officer	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
 SPARK Advisory Partners Limited (NOMAD)	
Neil Baldwin	+44 (0) 203 368 3550
 Stanford Capital Partners (Joint Broker)	
Patrick Claridge, Bob Pountney	+44 (0) 203 650 3650
 SI Capital (Joint Broker)	
Nick Emerson	+44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a first-in class "immune tolerance restorer" for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases that share the same mechanism of action.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPQKKBPOBDDABB